{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:30Z","timestamp":1777934610922,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bevacizumab is a monoclonal antibody for the vascular endothelial growth factor receptor and is utilized in the treatment of various tumors. Gastrointestinal perforation\/fistula, heart failure, hemorrhage, hypertension, proteinuria\/nephrotic syndrome, thromboembolism, posterior reversible encephalopathy syndrome, and necrotizing fasciitis are serious side effects of bevacizumab. Bevacizumab associated de novo brain arterio-venous malformation formation has not been documented in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>Here, we presented a 35-year-old female patient with recurrent high-grade glial tumor who developed multiple supra- and infratentorial de novo arterio-venous malformations after receiving the last dose of bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>Intervention options for the adverse effect were limited. In fact, there was no chance of intervention because the patient died for another reason.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Based on this experience, it can be hypothesized that bevacizumab may induce de novo arterio-venous malformations in the brain as a result of arterial and venous thrombotic effects. Additional studies should be done to clarify the causal relationship between bevacizumab and arterio-venous malformations in primary brain tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231171113","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T03:14:49Z","timestamp":1681960489000},"page":"577-581","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-3391","authenticated-orcid":false,"given":"Aysenur","family":"Elmali","sequence":"first","affiliation":[{"name":"Elazig Fethi Sekin City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahsan","family":"Gocmen","sequence":"additional","affiliation":[{"name":"Hacettepe University, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[{"name":"Hacettepe University, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gozde","family":"Yazici","sequence":"additional","affiliation":[{"name":"Hacettepe University, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1"},{"key":"e_1_3_2_3_2","volume-title":"Clinical and research information on drug-induced liver injury [Internet]","author":"LiverTox","year":"2012","unstructured":"LiverTox. Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70314-6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now035"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707358"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.006278."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/02688697.2018.1478060"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199610000-00004"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.11.021"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829c5cd5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8201"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3875"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.656"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.12.002"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231171113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231171113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231171113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:19Z","timestamp":1777688899000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231171113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10781552231171113"],"URL":"https:\/\/doi.org\/10.1177\/10781552231171113","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}